# Comparison between wharton’s jelly and collagen natural hydrogels for human ovarian follicle transplantation as an artificial ovary

**Authors:** Farnaz Tajbakhsh, Mohammad Kazemi Ashtiani, Somayeh Tavana, Ashraf Moini, Rouhollah Fathi

PMC · DOI: 10.1371/journal.pone.0329690 · PLOS One · 2025-08-14

## TL;DR

This study compares two natural hydrogels for creating artificial ovaries to improve fertility in cancer patients.

## Contribution

The study introduces a novel comparison of Wharton’s Jelly and Collagen hydrogels for human ovarian follicle transplantation.

## Key findings

- Wharton’s Jelly hydrogel better supported follicle growth compared to Collagen hydrogel.
- FSH injection improved granulosa cell differentiation in the Wharton’s Jelly group.
- EPO injection increased blood vessels in both hydrogel groups.

## Abstract

Artificial ovary (AO) is a bioengineered approach aimed at increasing fertility potential in certain cases, especially in women and prepubertal girls with a history of cancer. Some natural and synthetic materials can be used for ovary bioengineering. In the current study, we compared two natural hydrogel composites containing alginate (Alg): Wharton’s Jelly (WJ/Alg) and Collagen (Col/Alg) as models for human AO. In total, six experimental groups were designed: WJ/Alg, Col/Alg, WJ/Alg+FSH, Col/Alg+FSH, WJ/Alg+EPO, and Col/Alg+EPO (n = 60). In each group, 40 isolated human ovarian follicles were seeded in 10 µl of the desired hydrogel and xenotransplanted into the right side of the peritoneum in ovariectomized NMRI mice for 1 week. FSH (7.5 IU) and Erythropoietin (EPO; 200 IU/kg as an angiogenic factor) were injected every other day. Histological and immunohistochemical assessments for Vimentin, CD45, and Ki67; Gene expression analysis for GDF9, Vegf, and CD45; and hormonal assays for estradiol and progesterone were performed. Histological staining showed that WJ/Alg can support follicle growth. In contrast, most of follicles in Col/Alg remained at the primordial stage. Although FSH injection helped granulosa cells differentiation, especially in the WJ/Alg group (507.6 ± 134.1 vs 1444 ± 493.6), and EPO injection increased blood vessels in both groups (p-value<0.0001), the follicles could not preserve in the experimental groups. In addition, there were no significant differences in gene expression and hormonal assays across all groups. Based on the histological analysis, the WJ/Alg-base artificial ovary provided better support for follicle development after 1 week compared to the other groups. In addition, Adjusting FSH and EPO dosage may improve follicle survival and growth in future studies.

## Linked entities

- **Genes:** GDF9 (growth differentiation factor 9) [NCBI Gene 2661], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788]
- **Proteins:** PRELID1 (PRELI domain containing 1), PTPRC (protein tyrosine phosphatase receptor type C), Mki67 (antigen identified by monoclonal antibody Ki 67)
- **Chemicals:** Erythropoietin (PubChem CID 92043599), estradiol (PubChem CID 450), progesterone (PubChem CID 5994)

## Full-text entities

- **Genes:** RNASE1 (ribonuclease A family member 1, pancreatic) [NCBI Gene 6035] {aka RAC1, RIB1, RNS1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, GDF9 (growth differentiation factor 9) [NCBI Gene 2661] {aka POF14}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, EPO (erythropoietin) [NCBI Gene 2056] {aka DBAL, ECYT5, EP, MVCD2}, Epo (erythropoietin) [NCBI Gene 13856], VIM (vimentin) [NCBI Gene 7431], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** AO (MESH:D010051), cancer (MESH:D009369), premature ovarian insufficiency (MESH:D016649), WJ (MESH:D010300), cardiac failure (MESH:D006333), SCID (MESH:D053632), intervertebral disc degeneration (MESH:D055959), necrosis (MESH:D009336), inflammatory (MESH:D007249), hypoxia (MESH:D000860)
- **Chemicals:** Base (-), chloroform (MESH:D002725), PEG (MESH:D011092), glycosaminoglycans (MESH:D006025), HCl (MESH:D006851), FSH (MESH:D005640), progesterone (MESH:D011374), H&amp;E (MESH:D006371), oxygen (MESH:D010100), hydrogen peroxide (MESH:D006861), CaCl2 (MESH:D002122), xylazine (MESH:D014991), Trizol (MESH:C411644), 3,3'-diaminobenzidine (MESH:D015100), Neutral Red (MESH:D009499), paraformaldehyde (MESH:C003043), TBS (MESH:D013725), estradiol (MESH:D004958), Alg (MESH:D000464), 4`,6-diamidino-2-phenylindole (MESH:C007293), nitrogen (MESH:D009584), NaCl (MESH:D012965), Hematoxylin (MESH:D006416), Acetic acid (MESH:D019342), phenol (MESH:D019800), Isopropanol (MESH:D019840), Ethanol (MESH:D000431), MgCl2 (MESH:D015636), NR (MESH:C018613), H2O (MESH:D014867), NaOH (MESH:D012972), EDTA (MESH:D004492), SDS (MESH:D012967), hyaluronan (MESH:D006820), chitosan (MESH:D048271), eosin (MESH:D004801), SYBR Green (MESH:C098022), sodium citrate (MESH:D000077559), paraffin (MESH:D010232)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** WJ — Mus musculus (Mouse), Hybridoma (CVCL_U609)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12352639/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12352639/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12352639/full.md

---
Source: https://tomesphere.com/paper/PMC12352639